Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioLineRx, Israel’s Biotech Incubator, Nearing Major Inflection Points

This article was originally published in The Pink Sheet Daily

Executive Summary

Funded in part by the Israeli government, BioLineRx believes it is about to score big with a cardiology drug being developed under FDA’s regulatory pathway for devices, as well as a schizophrenia candidate that could improve patients’ cognition.

You may also be interested in...

Deals Of The Week: Celgene/Acetylon, Cytomedix/Aldagen, Vernalis/Tris Pharma

CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.

Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.

The Existential Dilemma of Israeli Biotech

Israel's biotech industry -- a scientific and entrepreneurial dynamo but starved for capital, infrastructure, and managerial experience -- is facing its existential dilemma. For some, the industry's current problems are merely a reflection of economic Darwinism; others are planning more radical financing innovations. Meanwhile, the relatively rich in Israel, some of the incubators like Clal, and especially the country's biggest company, Teva, are soaking up the available opportunities for relatively little money.


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts